426 related articles for article (PubMed ID: 29886103)
21. Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study.
Zhang X; Huang J; Peng Z; Lu X; Yang X; Ye K
Eur J Vasc Endovasc Surg; 2021 Mar; 61(3):484-489. PubMed ID: 33388238
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis.
Delgado MG; Seijo S; Yepes I; Achécar L; Catalina MV; García-Criado A; Abraldes JG; de la Peña J; Bañares R; Albillos A; Bosch J; García-Pagán JC
Clin Gastroenterol Hepatol; 2012 Jul; 10(7):776-83. PubMed ID: 22289875
[TBL] [Abstract][Full Text] [Related]
23. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
25. Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome.
Antignani PL; Allegra C; Fareed J
Int Angiol; 2019 Feb; 38(1):17-21. PubMed ID: 30465419
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial.
Kang JM; Park KH; Ahn S; Cho S; Han A; Lee T; Jung IM; Kim JY; Min SK
Sci Rep; 2019 Dec; 9(1):20356. PubMed ID: 31889152
[TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.
Senzolo M; M Sartori T; Rossetto V; Burra P; Cillo U; Boccagni P; Gasparini D; Miotto D; Simioni P; Tsochatzis E; A Burroughs K
Liver Int; 2012 Jul; 32(6):919-27. PubMed ID: 22435854
[TBL] [Abstract][Full Text] [Related]
29. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
30. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis.
Artaza T; Lopes M; Romero M; Gómez AZ; de la Cruz G; Sánchez JJ; González C; Gómez R
Gastroenterol Hepatol; 2018 Dec; 41(10):611-617. PubMed ID: 30049580
[TBL] [Abstract][Full Text] [Related]
32. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR;
Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435
[TBL] [Abstract][Full Text] [Related]
33. The Efficacy and Safety of Anticoagulants in the Treatment of Cirrhotic Portal Vein Thrombosis: A Systematic Review and Meta-Analysis.
Zhang Z; Zhao Y; Han B; Zhu Z; Sun L; Cui X
Clin Appl Thromb Hemost; 2022; 28():10760296221104797. PubMed ID: 35656719
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis.
Ai MH; Dong WG; Tan XP; Xu L; Xu C; Zhang Q; Zhang Y; Li J
Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1395-1400. PubMed ID: 32675774
[TBL] [Abstract][Full Text] [Related]
35. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
36. Low-molecular-weight heparin followed by rivaroxaban for acute occlusive portomesenteric vein thrombosis in a cirrhotic patient treated with multiple endoscopic variceal procedures.
Xu X; Guo X; Wang R; Wang L; Li Q; Yi F; Li H; Qi X
Ann Hepatol; 2020; 19(5):573-577. PubMed ID: 31521463
[TBL] [Abstract][Full Text] [Related]
37. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation.
Werner KT; Sando S; Carey EJ; Vargas HE; Byrne TJ; Douglas DD; Harrison ME; Rakela J; Aqel BA
Dig Dis Sci; 2013 Jun; 58(6):1776-80. PubMed ID: 23314858
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban for the treatment of cerebral venous thrombosis.
Esmaeili S; Abolmaali M; Aarabi S; Motamed MR; Chaibakhsh S; Joghataei MT; Mojtahed M; Mirzaasgari Z
BMC Neurol; 2021 Feb; 21(1):73. PubMed ID: 33588777
[TBL] [Abstract][Full Text] [Related]
39. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.
La Mura V; Braham S; Tosetti G; Branchi F; Bitto N; Moia M; Fracanzani AL; Colombo M; Tripodi A; Primignani M
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1146-1152.e4. PubMed ID: 29066371
[TBL] [Abstract][Full Text] [Related]
40. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
